Trials / Completed
CompletedNCT05262777
Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies
A Randomized, Evaluator-blinded, Parallel Group, Comparator-controlled, Multicenter Study to Evaluate the Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 211 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0112 for cheek augmentation and correction of midface contour deficiencies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | GP0112 | Injectable gel |
| DEVICE | Restylane Lyft Lidocaine | Injectable gel |
Timeline
- Start date
- 2022-05-02
- Primary completion
- 2023-01-17
- Completion
- 2024-03-05
- First posted
- 2022-03-02
- Last updated
- 2024-04-09
Locations
15 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT05262777. Inclusion in this directory is not an endorsement.